Ulcerative Colitis Market Size (2024 - 2029)

The ulcerative colitis market size is projected to experience growth over the forecast period, driven by advancements in treatment options and increased focus from market players on product development. The impact of COVID-19 has shifted attention back to ulcerative colitis treatments, with new regulatory approvals enhancing market dynamics. The rising demand for innovative therapies, such as fecal microbiota transplantation and Janus kinase inhibitors, is expected to contribute to market expansion. Despite these positive trends, challenges such as unmet clinical needs and medication side effects may hinder market growth.

Market Size of Ulcerative Colitis Industry

Ulcerative Colitis Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 3.75 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Ulcerative Colitis Market Major Players

*Disclaimer: Major Players sorted in no particular order

Ulcerative Colitis Market Analysis

The ulcerative colitis market size is expected to grow from USD 7.49 billion in 2023 to USD 9.00 billion by 2028, registering a CAGR of 3.75% during the forecast period.

COVID-19 severely impacted various treatment markets, including the ulcerative colitis market, due to an increased preference for COVID-19 treatment, supply chain alterations, and increased research studies on COVID-19 products compared with other treatment products. However, due to the decreased COVID-19 effect on the public, the market players focused on various disease treatments, including ulcerative colitis treatment products. For instance, as per AbbVie Inc's 2022 annual report, the net revenue of Rinvoq (upadacitinib) increased 58% in 2022, which was favorably impacted by recent regulatory approvals and expansion of Rinvoq for the treatment of ulcerative colitis and other treatments. This shows the new approval of ulcerative colitis treatments after the COVID-19 pandemic, which is expected to significantly impact the market over the coming years.

Factors such as the growing burden of ulcerative colitis, increasing patient assistance programs, technological advancements, and research drive the market's growth.

The demand for market products is anticipated to rise due to the growing advances in treating ulcerative colitis. For instance, as per the study report published by Frontiers in Pharmacology in September 2022, the research studies on fecal microbiota transplantation, anti-integrin antibodies, Janus kinase inhibitors, and anti-tumor necrosis factor drugs for ulcerative colitis continued to grow over the coming years which likely increased the demand for more advanced treatment products and drives the market growth over the forecast period.

In addition, the increasing involvement of key players in product development related to the field is anticipated to drive the market's growth. For instance, in May 2023, Janssen Global Services, LLC released new safety and efficacy data from a Phase III trial investigating Tremyfa (guselkumab) in adults with moderately to severely active ulcerative colitis (UC). This large focus of market players on developing new drugs for treatment is expected to boost the market's growth in the future. Additionally, the approval of the drugs is also propelling the market's growth. For instance, in November 2021, Bristol Myers Squibb received marketing authorization from the European Commission for Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or are intolerant to either conventional therapy or a biologic agent. Thus, the factors above are expected to boost the market's growth over the forecast period.

However, factors such as high levels of unmet clinical need in ulcerative colitis (UC) and the side effects of medications are expected to impede market growth over the forecast period.

Ulcerative Colitis Industry Segmentation

As per the report's scope, ulcerative colitis is an inflammatory disease of the bowel that causes ulcers in the digestive tract. It affects the innermost lining of the large intestine (colon) and rectum. Symptoms usually develop over time rather than suddenly. The Ulcerative Colitis Market is Segmented by Drug Type (Anti-Inflammatory Drugs (Aminosalicylates, and Corticosteroids), Anti-TNF biologics, Immunosuppressants, Calcineurin Inhibitors, and Other Drug Types), Disease Type (Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, and Fulminant Colitis) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.

By Drug Type
Anti-Inflammatory Drugs
Aminosalicylates
Corticosteroids
Anti-TNF biologics
Immunosuppressants
Calcineurin Inhibitors
Other Drug Types
By Disease Type
Ulcerative Proctitis
Proctosigmoiditis
Left-sided Colitis
Pancolitis or Universal Colitis
Fulminant Colitis
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Ulcerative Colitis Market Size Summary

The ulcerative colitis market is poised for significant growth, driven by a combination of increasing disease prevalence, technological advancements, and active involvement of key industry players in product development. The market experienced disruptions due to the COVID-19 pandemic, which shifted focus towards COVID-19 treatments and research. However, as the pandemic's impact waned, attention returned to ulcerative colitis, with companies like AbbVie Inc. reporting substantial revenue increases from newly approved treatments. The market's expansion is further supported by ongoing research into innovative therapies, such as fecal microbiota transplantation and Janus kinase inhibitors, which are expected to enhance treatment options and drive demand.

North America is anticipated to lead the market, bolstered by the presence of major pharmaceutical companies and a high prevalence of ulcerative colitis. Regulatory approvals and funding for research in the region are also contributing to market growth. The market is characterized by a fragmented landscape with numerous players engaging in strategic initiatives like mergers and acquisitions to strengthen their positions. Notable activities include Merck & Co.'s acquisition of Prometheus Biosciences, aimed at advancing novel treatments for ulcerative colitis. Despite challenges such as unmet clinical needs and medication side effects, the market is expected to continue its upward trajectory, supported by the development of immunomodulators and other advanced therapeutic options.

Explore More

Ulcerative Colitis Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 High Global Incidence and Prevalence of Ulcerative Colitis

      2. 1.2.2 Technological Advancements

      3. 1.2.3 Increase in Patient Assistance Programs

    3. 1.3 Market Restraints

      1. 1.3.1 High Levels of Unmet Clinical Need in Ulcerative Colitis (UC)

      2. 1.3.2 Side-effects of Medications

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Buyers/Consumers

      2. 1.4.2 Bargaining Power of Suppliers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Drug Type

      1. 2.1.1 Anti-Inflammatory Drugs

        1. 2.1.1.1 Aminosalicylates

        2. 2.1.1.2 Corticosteroids

      2. 2.1.2 Anti-TNF biologics

      3. 2.1.3 Immunosuppressants

      4. 2.1.4 Calcineurin Inhibitors

      5. 2.1.5 Other Drug Types

    2. 2.2 By Disease Type

      1. 2.2.1 Ulcerative Proctitis

      2. 2.2.2 Proctosigmoiditis

      3. 2.2.3 Left-sided Colitis

      4. 2.2.4 Pancolitis or Universal Colitis

      5. 2.2.5 Fulminant Colitis

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Ulcerative Colitis Market Size FAQs

The Global Ulcerative Colitis Market is projected to register a CAGR of 3.75% during the forecast period (2024-2029)

AbbVie Inc. (Allergan, Inc.), Merck & Co., Inc.,, Novartis AG, Bausch Health Companies Inc. and Johnson & Johnson are the major companies operating in the Global Ulcerative Colitis Market.

Ulcerative Colitis Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)